Ocular Therapeutix (OCUL) Earnings Analysis

Ocular Therapeutix (OCUL) has no confirmed upcoming earnings date. Last quarter (2026-02-05) it beat with EPS -0.29 USD vs -0.33 USD est (+12.1%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -5.88.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does OCUL next report earnings?

No confirmed upcoming earnings date is currently scheduled for OCUL. This page updates as the calendar is published.

OCUL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-05-0.29 USD-0.33 USD+12.1%Beat
2025-05-05-0.37 USD-0.29 USD-27.6%Miss
2025-03-03-0.29 USD-0.24 USD-20.8%Miss
2024-11-14-0.26 USD-0.23 USD-13%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

OCUL valuation and analyst view

Trailing P/E-5.88
Trailing EPS-1.29629 USD
Price / book3.31
Dividend yield0.00%
Market cap1.90B
Analyst consensusBuy (17 buy / 2 hold / 0 sell)
Avg price target27.5 USD

Related research pages

Frequently asked questions

When is Ocular Therapeutix (OCUL)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for OCUL. This page updates as the calendar is published.

Did OCUL beat earnings last quarter?

In its 2026-02-05 report, OCUL posted EPS of -0.29 USD versus a -0.33 USD estimate — a beat of 12.1%.

What is OCUL's earnings track record?

Over the last 4 reported quarters with consensus data, OCUL beat estimates 1 times (25%).

What is OCUL's current P/E ratio and EPS?

OCUL trades at a trailing P/E of -5.88 on trailing EPS of -1.296290784522815 USD.

What do analysts rate OCUL?

Analyst consensus is "Buy" across 19 ratings (1 strong buy, 16 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 27.5 USD.